Processa Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 13
- Market Cap
- -
- Introduction
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.
Processa Pharmaceuticals Secures $452.5M Licensing Deal for Gastroparesis Drug PCS12852
Processa Pharmaceuticals has entered into a binding term sheet with Intact Therapeutics for the exclusive licensing of PCS12852, a 5-HT4 receptor agonist targeting gastroparesis and gastrointestinal motility disorders.
Processa Pharmaceuticals Doses First Patient in Phase II Trial of NGC-Cap for Metastatic Breast Cancer
Processa Pharmaceuticals has dosed the first patient in a Phase II clinical trial of Next Generation Capecitabine (NGC-Cap) for advanced or metastatic breast cancer.